A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
Public ClinicalTrials.gov record NCT07608354. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo in Adult Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Study identification
- NCT ID
- NCT07608354
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 326 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 11, 2026 (Actual)
- Primary completion
- Feb 6, 2029 (Estimated)
- Completion
- Feb 6, 2029 (Estimated)
- Last update posted
- Jul 14, 2026
2026 – 2029
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | La Jolla | California | 92037 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | Stanford | California | 94305 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Washington D.C. | District of Columbia | 20010 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | Miami | Florida | 33176 | — |
| Research Site | Weston | Florida | 33331 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Danville | Pennsylvania | 17822 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Salt Lake City | Utah | 84132 | — |
| Research Site | Falls Church | Virginia | 22042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07608354, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07608354 live on ClinicalTrials.gov.